Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Preemptive Dexamethasone , Paracetamol on Postoperative Period Following Adeno-tonsillectomy in Pediatric .
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Benha University
- Target Recruit Count
- 90
- Registration Number
- NCT05143762
- Locations
- 🇪🇬
Banha Faculity of Medicine, Banha, Elqalyoubea, Egypt
Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- Dow University of Health Sciences
- Target Recruit Count
- 170
- Registration Number
- NCT05142098
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 26
- Registration Number
- NCT05139043
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dexamethasone and Functional Outcome After TKA
- Conditions
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Slagelse Hospital
- Target Recruit Count
- 162
- Registration Number
- NCT05137080
- Locations
- 🇩🇰
Næstved, Slagelse og Ringsted Hospitals, Næstved, Denmark
🇩🇰Næstved, Slagelse and Ringsted Hospitals, Slagelse, Denmark
Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- CHA University
- Target Recruit Count
- 102
- Registration Number
- NCT05136560
- Locations
- 🇰🇷
Bundang CHA hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Samsung Hospital, Seoul, Korea, Republic of
Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 334
- Registration Number
- NCT05132920
- Locations
- 🇩🇪
Otto von Guericke University Magdeburg, Magdeburg, Sachsen-Anhalt, Germany
🇩🇪University Hospital Bonn, Bonn, NRW, Germany
🇩🇪University Hospital Leipzig, Leipzig, Sachsen, Germany
Effect of Dexmedetomidine on Prevention of Postoperative Nausea and Vomiting in Children
- Conditions
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 4
- Registration Number
- NCT05124067
- Locations
- 🇸🇦
Sharurah Armed Forces Hospital, Sharurah, Najran, Saudi Arabia
DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabeculectomy and Ahmed Valve Procedures
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Brian Jerkins, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05116345
- Locations
- 🇺🇸
Hamilton Eye Institute, Memphis, Tennessee, United States
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 82
- Registration Number
- NCT05096663
- Locations
- 🇺🇸
Kaiser Permanente West Los Angeles, Los Angeles, California, United States
🇺🇸Illinois CancerCare-Princeton, Princeton, Illinois, United States
🇺🇸UPMC-Mercy Hospital, Pittsburgh, Pennsylvania, United States
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 587
- Registration Number
- NCT05083169
- Locations
- 🇺🇸
Emory University - Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.